IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Merger Arb Mondays (20 Nov) - Eoflow, Origin, OreCorp, Azure, Hollysys, Toyo, Amara, Haitong Intl

EOFLOW/Medtronic Tender: Appeals Brief Is All Bark, No Bite

EOFLOW/Medtronic Tender: Pretrial Timetable and Latest Court Filings

EOFLOW/Medtronic Tender: Closing Date Extended to 3 January 2024

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>The KRX has completed its review and excluded <a href="https://www.smartkarma.com/entities/eoflow-co-ltd" target="_blank" data-smartkarma-citation="entities:36100:1" rel="noopener">Eoflow (294090 KS)</a> from the substantive review for listing eligibility. Therefore, trading will resume tomorrow, 16 November.</li>
<li>The shares should rise on trading resumption as Medtronic's tender remains in play, KRX's review supported Eoflow's business continuity and the short-selling ban-driven market rally.</li>
<li>Deal break risks remain significant. <a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a>’s long-dated closing date and lack of Eoflow integration job postings suggest it remains concerned about near-term unfavourable court rulings. </li>
</ul>


The KRX has completed its review and excluded Eoflow (294090 KS) from the substantive review for listing eligibility. Therefore, trading will resume tomorrow, 16 November.
The shares should rise on trading resumption as Medtronic's tender remains in play, KRX's review supported Eoflow's business continuity and the short-selling ban-driven market rally.
Deal break risks remain significant. Medtronic Plc (MDT US)’s long-dated closing date and lack of Eoflow integration job postings suggest it remains concerned about near-term unfavourable court rulings. 


EOFLOW/Medtronic Tender: Trading Suspension Lifted, Now for the Hard Part